ANR-001.1 (latanoprost + minoxidil)
A fixed combination of latanoprost and minoxidil, from a company founded to develop it for women.
- Developed by
- Aneira Pharma
- Current phase
- Phase 0
- Indications
- Androgenetic alopecia, Female pattern hair loss
- Also known as
- ANR-001, ANR001
- Last public activity
- Never
- Record confidence
- Low
A very small exploratory human study, usually microdosing.
Why it matters
Two molecules already used for hair, combined. That lowers the scientific risk and raises the regulatory bar — a fixed-dose combination has to show it beats each component alone, not merely placebo. Nothing is registered on ClinicalTrials.gov, so this row rests on the company's own description and is marked LOW accordingly.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Aneira Pharma — pipeline — Company release